緩和医療が求める院内製剤～医師の視点から～

DOI Web Site Web Site PubMed 参考文献1件

書誌事項

タイトル別名
  • Hospital Formulations for Palliative Medicine
  • Symposium Review 緩和医療が求める院内製剤 : 医師の視点から
  • Symposium Review カンワ イリョウ ガ モトメル インナイ セイザイ : イシ ノ シテン カラ

この論文をさがす

抄録

　Palliative care had a role in maintaining and improving the patient's QOL. To optimize symptomatic management, that cannot be controlled using commercial formulations, in-house pharmaceutical preparations customized to meet an individual's clinical needs are sometimes administered. Despite a growing arsenal of oncology drugs, opioids, and other compounds, many elderly cancer patients have a wide spectrum of comorbid conditions that require the help of skilled pharmacists. Although drugs prepared in in-house pharmacies can be customized to the conditions of individual patients, their preparation is time- and resource-intensive, and their benefits sometimes do not outweigh the costs. In addition, it is often difficult to predict the required amount of a drug that will be dispensed to a very small number of patients via these custom formulations. However, we occasionally experience cases in which hospital formulations (HF) significantly alleviate symptoms and improve the QOL of patients with cancer. In fact, efforts to develop HF of palliative medications sometimes pave the way to new marketable products. In fact, collaborations between physicians and pharmacists have indeed produced new types of medications, which have been further developed into commercial painkillers by drug manufacturers. This article presents examples of HF used in clinical practice. It also discusses the future need for HF, taking note of the ongoing shift towards outpatient oncology care. Regarding the use of HF, we believe it is always important to ensure patient safety, to obtain informed consent, and to follow up.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 138 (6), 757-762, 2018-06-01

    公益社団法人 日本薬学会

参考文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ